Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
Stockchase Opinions

Benj GallanderStressgen Biotechnologies CorpSSB.TOPAST TOP PICKNov 09, 2004

(A Top Pick June 14/04. Down 56%.) They continue to lose money. They'll have to get something through their pipeline quickly that deals with cancer. Doesn't look good.
$0.46

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

DON'T BUY
A lottery ticket! The company has gone into orphan status. Have disappointed investors many, many times. They keep needing money. Very risky.
DON'T BUY
Trying to raise $50 million which is equivalent/more than their entire market cap.
TOP PICK
Holds this stock personally. Risky could double.
TRADE
A field that you have to be really wary of. Many of them have a very high burn rate. Although their trials were fast tracked, this does not necessarily mean continued success.
DON'T BUY
Have restructured and will need more money.
BUY
Very volatile. Developing a product for HBV (a sexually transmitted disease), which has a large market. In phase two. Has a partnership with Roach and has enough cash to probably last into 2005.
DON'T BUY
On their watch list. Lost a lot of maney last year.
BUY ON WEAKNESS
A speculative stock. Has to move through the regulatory gateway. Meets a lot of technical resistance at the $1.81 level. Try to pick up near its support level of $1.25.
BUY
They are far enough into their trials that investors are now paying more attention. Relatively cheap. Management is OK.
BUY
Outlook is quite good and the price is at a good level.
BUY
At a good level. Has mad a good agreement with a large pharmaceutical.
WEAK BUY
In the final stage of their clinical trials. Will be a couple of years before you know if the product works.
WEAK BUY
Well along on the approval line. Product seems to be good. The sector is suffering. A higher risk.
WAIT
Fairly risky, but a good risk/reward ratio. In phase 3 trials. Could double if they get into a good partnership.